Indolent T-cell lymphoproliferative disorder of the stomach successfully treated by radiotherapy.


Journal

Journal of clinical and experimental hematopathology : JCEH
ISSN: 1880-9952
Titre abrégé: J Clin Exp Hematop
Pays: Japan
ID NLM: 101141257

Informations de publication

Date de publication:
2020
Historique:
entrez: 1 4 2020
pubmed: 1 4 2020
medline: 14 1 2021
Statut: ppublish

Résumé

Successful treatment of indolent T-cell lymphoproliferative disorder of the gastrointestinal tract (ITLPDGI) by chemotherapy is rare and watchful waiting is often performed for asymptomatic patients. We report a case of ITLPDGI successfully treated by involved field radiotherapy (IFRT). The patient presented with slow ITLPDGI localised to the stomach with mild symptoms. IFRT (30 Gy/20f) was administered, after which endoscopy revealed resolution of lesions and blood vessel appearance, and absence of proliferating abnormal lymphocytes was confirmed by biopsy. The patient remains lymphoma-free 1 year post-treatment. Although long-term follow-up and additional cases are essential for the evaluation of IFRT as a treatment option for localised ITLPDGL, complete remission after relatively low-dose IFRT is promising, particularly as this has been rarely achieved by chemotherapy.

Identifiants

pubmed: 32224564
doi: 10.3960/jslrt.19022
pmc: PMC7187675
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-10

Références

Blood. 2011 Feb 3;117(5):1447-52
pubmed: 20966166
Blood. 2010 Dec 16;116(25):5631-7
pubmed: 20829373
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Hematol Oncol. 2017 Mar;35(1):3-16
pubmed: 27353398
Blood. 2013 Nov 21;122(22):3599-606
pubmed: 24009234
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Br J Haematol. 2013 Apr;161(2):214-23
pubmed: 23432459
Hum Pathol. 2013 Sep;44(9):1927-36
pubmed: 23706909
Blood. 2004 Apr 1;103(7):2474-9
pubmed: 14645001
Blood. 2018 May 17;131(20):2262-2266
pubmed: 29592893

Auteurs

Naoki Takahashi (N)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Kunihiro Tsukasaki (K)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Mika Kohri (M)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Yu Akuzawa (Y)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Tsuyoshi Saeki (T)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Daisuke Okamura (D)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Maho Ishikawa (M)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Tomoya Maeda (T)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Nobutaka Kawai (N)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Akira Matsuda (A)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Eiichi Arai (E)

Department of Pathology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Shin Arai (S)

Department of Gastroenterology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Norio Asou (N)

Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH